多西紫杉醇联合奥沙利铂治疗晚期胃癌的临床疗效观察

Treatment Effect of Docetaxel Associated with Oxaliolatin on Advanced Gastric Cancer

目的:观察多西紫杉醇(TXT)联合奥沙利铂(OXA)方案治疗晚期胃癌的临床疗效及不良反应。方法:对38例晚期胃癌患者,采用TXT 75mg/m2,静脉滴注(第1天);OXA 130 mg/m2,静脉滴注(第2天);21天为1个周期,至少2个周期后评价疗效。结果:38例患者均按计划完成(2～6)个周期化疗,共完成148个周期,均可评价疗效。其中CR 2例,PR 21例,NC 9例,PD 6例,RR(CR+PR)%为60.52%;KPS改善30例(78.94%);中位无进展生存期(PFS)6.2个月,中位总生存期(OS)11.9个月。不良反应主要是骨髓抑制,(Ⅲ～Ⅳ)级白细胞减少率达63.16%,其次为脱发、胃肠道反应及周围神经毒性,均为可逆性。本组无治疗相关性死亡。结论:多西紫杉醇联合奥沙利铂治疗晚期胃癌疗效确切,毒性反应轻,患者耐受性好,且两药联合方案与在此基础上联用氟尿嘧啶类药物的三药联合方案疗效相似,即减轻了毒副反应,又节省了治疗费用,给药方便,值得临床推广应用。

Objective：To evaluate the treatment effects and toxicity of docetaxel associated with oxaliplatin on advanced gastric cancer.Methods：38 patients with advanced gastric cancer were treated with docetaxel（75mg/m2,intravenous drip,the day 1） pus oxaliplatin（130mg/m2,the day 2） for 2-6 cycle（21 days for 1cycle）,and the results were assessed after 2 cycle treatment at least.Results：Of 38 patients,the cases of complete remission（CR）,partial remission（PR）,no change（NC） and progressive disease（PD） was 2,21,9 and 6,respectively.The total effective（CR＋PR） rate was 60.52%,30 78.94%（30 patients） for improvement of Karnofsky（KPS） score,6.2 months for progression-free survival（PFS）,11.9 months for overall survival（OS）.The major toxicities included of myelosuppression,alopecia,nausea vomiting,and peripheral neuritis;63.16% of 38 patients had（Ⅲ～Ⅳ）grade leucopenia,nonetheless,they was reversible.Conclusions：Treatment of docetaxel associated with oxaliplatin for advance gastric cancer is an effective,and can be tolerated well;as well as decreases of toxicity.